延长肽受体放射性核素治疗:评估接受超过四个治疗周期的神经内分泌肿瘤患者的肾毒性与疗效
本回顾性分析纳入至少接受四个PRRT周期的神经内分泌肿瘤患者,比较标准四周期组与超过四周期延长治疗组的肾毒性和生存。延长治疗组中位总生存72.8个月 vs 标准组52.8个月,肾毒性指标无显著差异。
要点
- 延长PRRT超过四周期未显著增加肾毒性,两组肌酐水平及CTCAE分级无显著差异。
- 延长治疗组中位总生存72.8个月 vs 标准组52.8个月,HR 0.580。
- 延长治疗组疾病特异性生存优于标准组,HR 0.599。
核心结论
- 延长PRRT超过标准四周期可能是NET患者安全有效的治疗策略,对标准治疗后复发或进展的患者可能尤其获益。
研究设计与样本
- 回顾性分析纳入至少接受四个PRRT周期且有随访数据的患者,标准组281例,延长治疗组356例。
主要发现
- 治疗后平均肌酐水平标准组89.30 ± 51.19 μmol/L vs 延长治疗组93.20 ± 55.98 μmol/L(P = 0.364),两组CTCAE肌酐分级无统计学显著差异(P = 0.448)。
- 肾脏不良事件发生率标准组0.4% vs 延长治疗组1.1%。
- 中位随访88.3个月,中位总生存延长治疗组72.8个月 vs 标准组52.8个月。
- Cox回归分析显示延长治疗组总生存HR 0.580(P < 0.001),疾病特异性生存HR 0.599(P < 0.001)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Currently, the most used peptide receptor radionuclide therapy (PRRT) regimen for neuroendocrine tumors comprises 4 treatment cycles, and there is not enough large-scale data to support the safety of more individualized extended PRRT. This study aims to evaluate the therapeutic effectiveness and potential nephrotoxicity related to PRRT using more than four treatment cycles. METHODS: In this retrospective analysis, we included patients who had received at least four PRRT cycles and had available follow-up data. We analyzed renal function indicators before and after multiple treatments, comparing nephrotoxicity in patients receiving four cycles ("standard") with those receiving more than four ("extended treatment"). Nephrotoxicity was assessed via creatinine levels and CTCAE creatinine grades. Treatment effectiveness was gauged using Kaplan-Meier survival analysis, focusing on overall survival and disease-specific survival (DSS). Statistical analyses were performed using SPSS version 26 (IBM), R 4.2.3, and GraphPad Prism 9.0.0. Statistical significance was defined as a P-value of less than 0.05. RESULTS: Our study cohort consisted of 281 patients in the standard group and 356 in the extended treatment group. No significant differences in baseline characteristics or renal function were noted between the two groups pre-treatment. Mean post-treatment creatinine levels did not significantly differ between the standard (89.30 ± 51.19 μmol/L) and extended treatment groups (93.20 ± 55.98 μmol/L; P = 0.364). Similarly, there was no statistical significance between the CTCAE creatinine grades of the two groups (P = 0.448). Adverse renal events were observed in 0.4% of patients in the standard group and 1.1% in the extended treatment group. After a median follow-up time of 88.3 months, we found that median overall survival was significantly higher in the extended treatment group (72.8 months) compared to the standard treatment group (52.8 months). A Cox regression analysis further supported these findings, indicating a better prognosis for the extended treatment group in terms of overall survival (HR: 0.580, P < 0.001) and DSS (HR: 0.599, P < 0.001). CONCLUSION: Our findings suggest that extending PRRT treatment beyond the standard four cycles may be a safe and effective therapeutic strategy for NET patients. This approach could be particularly beneficial for patients experiencing disease recurrence or progression following standard treatment.
引用
- Baum RP, Fan X, Jakobsson V, et al. Extended peptide receptor radionuclide therapy: evaluating nephrotoxicity and therapeutic effectiveness in neuroendocrine tumor patients receiving more than four treatment cycles. Eur J Nucl Med Mol Imaging. 2023. PMID: 38040931. doi:10.1007/s00259-023-06544-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。